Open AccessMicrosomal Transfer Protein Inhibitors, New Approach for Treatment of Familial Hypercholesterolemia, Review of the Literature, Original Findings, and Clinical Significance
Author(s) -
Kolovou Genovefa,
Vasiliadis Ioannis,
Gontoras Nikos,
Kolovou Vana,
Hatzigeorgiou Georgios
Publication year - 2015
Publication title -
cardiovascular therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 46
eISSN - 1755-5922
pISSN - 1755-5914
DOI - 10.1111/1755-5922.12105
Subject(s) - ezetimibe , medicine , familial hypercholesterolemia , microsomal triglyceride transfer protein , cholesterylester transfer protein , ldl receptor , disease , bioinformatics , pharmacology , lipoprotein , cholesterol , very low density lipoprotein , biology
Summary The genetic causes of cholesterol metabolism disorders usually lead to premature atherosclerosis. The most well recognized genetically caused hypercholesterolemia is familial hypercholesterolemia. Although the disease is well known, as the discovery of low‐density lipoprotein receptor, the classical treatment with lipid‐lowering drugs (statins, fibrates, ezetimibe, colesevelam) is still not adequate and new options are seeking. This review is an attempt to analyze the microsomal transfer protein ( MTP ) inhibitors as a new approach for treatment of familial hypercholesterolemia, to reviews the literature according to MTP inhibitors and finally to provide original findings.